Haemonetics Projects 6%-9% Organic Growth Through FY 2027 Amid Plasma Segment Expansion
Haemonetics Corporation (HAE) reported strong financial performance for the second quarter of fiscal year 2027, driven by growth across its Plasma, Blood Management, and Interventional Technologies segments. The company achieved 10% organic revenue growth in Q2 and 8% in the first half of the fiscal year. Looking ahead, management has provided long-term guidance projecting organic revenue growth between 6% and 9% through fiscal year 2027. A key driver for this sustained growth will be the continued scaling of the CSL Persona PLUS rollout throughout the calendar year 2027.
Tickers: $HAE
Topics: blood management interventional technologies plasma revenue growth